IDs are a wide range of conditions driven by Chronic Inflammatory (CI) processes. They encompass most chronic Non-Communicable Diseases (NCDs) such as cardiovascular conditions, cancers, diabetes, arthritis, neurodegenerative disorders, and bowel diseases. Chronic Inflammatory Diseases (CIDs) are a major cause of sickness and premature death globally.
0
Bn
of the
0
Bn
humans currently alive are expected to get sick and die due to a CIDs.
0
Bn
of the
0
Bn
humans currently alive are expected to get sick and die due to a CIDs.
0
Bn
of the
0
Bn
humans currently alive are expected to get sick and die due to a CIDs.
It has been estimated that the global costs of just four chronic diseases – cancer, diabetes, heart disease and respiratory disease – will reach
$
0
trillion by 2030*
From late action
To early diagnostic and prevention
The World Economic Forum estimates that the global costs of just four chronic diseases –cancer,diabetes, heart disease and respiratory disease –will reach $47 trillion by 2030
All these conditions are characterised by CI processes and there are no reliable, prognostic biomarkers to measure it.
Medics diagnose Chronic Inflammatory Diseases only after tissue and organ damage has occurred and are unable to reliably identify the most vulnerable patients to prevent development of the disease at the early stage.
For many syndromic IDs, medics cannot readily distinguish between the different possible types of immune dysfunction, so they use imprecise therapies that alleviate symptoms rather than identify and treat causes.
From imprecision
To personalised treatment solutions
From expensive
To affordable and accessible to all
The lack of affordable and scalable prognostic and predictive tests leads to mounting healthcare costs. Patients with the worst health outcomes are only identified when they have serious inflammatory episodes. Hence costs to treat them are significantly higher.
FROM LATE ACTION
TO DIAGNOSTIC AND PREVENTION
Medics diagnose Chronic Inflammatory Diseases only after tissue and organ damage has occurred and are unable to reliably identify the most vulnerable patients to prevent development of the disease at the early stage.
FROM IMPRECISION
TO PERSONALISED TREATMENT SOLUTIONS
For many syndromic IDs, medics cannot readily distinguish between the different possible types of immune dysfunction, so they use imprecise therapies that alleviate symptoms rather than identify and treat causes.
FROM EXPENSIVE
To affordable and accessible to all
The lack of affordable and scalable prognostic and predictive tests leads to mounting healthcare costs. Patients with the worst health outcomes are only identified when they have serious inflammatory episodes. Hence costs to treat them are significantly higher.
FROM LATE ACTION
TO DIAGNOSTIC AND PREVENTION
Medics diagnose Chronic Inflammatory Diseases only after tissue and organ damage has occurred and are unable to reliably identify the most vulnerable patients to prevent development of the disease at the early stage.
FROM IMPRECISION
TO PERSONALISED TREATMENT SOLUTIONS
For many syndromic IDs, medics cannot readily distinguish between the different possible types of immune dysfunction, so they use imprecise therapies that alleviate symptoms rather than identify and treat causes.
FROM EXPENSIVE
To affordable and accessible to all
The lack of affordable and scalable prognostic and predictive tests leads to mounting healthcare costs. Patients with the worst health outcomes are only identified when they have serious inflammatory episodes. Hence costs to treat them are significantly higher.
Our Story
Avenna was spun out from Ludger in 2017 to translate a promising glycomic research programme into practical and affordable diagnostic tools for inflammatory diseases. We are now working with scientists, clinicians, academics and patient groups, to further develop this assay into precision medicine clinical biomarkers and tests to enable early detection and treatment personalisation for inflammatory diseases.
Vision
To become a world leader in development of personalised precision healthcare solutions for inflammatory diseases. These solutions will enable early detection, treatment personalisation for individuals living with inflammatory conditions, will increase their healthspan and reduce healthcare costs.
Mission
Avenna translates most promising research grade technologies into practical, affordable, and accessible clinical tools to enable precision medicine approach to treat inflammatory diseases.
Our midterm goal is to further develop and commercialise, blood glycomic biomarkers for inflammatory bowel, brain, and skin diseases.
Research
Our R&D programmes focus on the development of prognostic and predictive glycomic blood biomarkers and Immunofrailty Model.
These innovations will enable early detection and treatment personalisation for Inflammatory conditions in clinical practice.
Our Collaborators
